Generics - Asia-Pacific, Roche

Filter

Current filters:

Asia-PacificRoche

Popular Filters

Celltrion’s trastuzumab biosimilar, Herzuma, approved in South Korea

16-01-2014

South Korean biopharmaceutical firm Celltrion has received approval for its cancer treatment biosimilar…

Asia-PacificBiosimilarsCellTrionGenericsHerceptinHerzumaOncologyRegulationRoche

Mylan-Biocon Herceptin biosimilar gets first Indian approval

Mylan-Biocon Herceptin biosimilar gets first Indian approval

26-11-2013

US generic major Mylan says that its partner, India-based biotechnology firm Biocon has received approval…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazMylan LaboratoriesOncologyRegulationRoche

Intas Pharma settles with Roche over Xeloda; Merck & Co wins injunction against Aprica

25-06-2013

Indian drugmaker Intas Pharmaceuticals and its wholly owned subsidiary Accord Healthcare have entered…

Aprica PharmaceuticalsAsia-PacificDiabetesGenericsIntas PharmaceuticalsMerck & CoNorth AmericaOncologyPatentsRocheXeloda

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib

15-01-2013

The Indian government's move to issue compulsory licences to three more patented cancer drugs has left…

Asia-PacificAvastinBristol-Myers SquibbGenericsIxempraOncologyPatentsPharmaceuticalRocheSprycel

AstraZeneca drops early-stage obesity drug; Roche loses out on Indian Tarceva dispute

10-09-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has told its development partner Palatin Technologies…

Asia-PacificAstraZenecaCiplaErlocipGenericsMetabolicsOncologyPalatin TechnologiesPatentsPharmaceuticalResearchRocheTarceva

Back to top